A new report from Bloomberg states that documents produced in the ongoing Yaz/Yasmin products liability litigation show that Bayer company officials may have tried to mislead consumers about the risk of intravenous thomboembolisms (VTE). According to the article, the lead author of a European study which concluded that Yasmin did not increase the risk of blood clots, was himself involved in the development of the drug during his tenure at Schering AG, a company acquired by Bayer in 2006. The author's association with Schering and involvment in the development of Yasmin was not disclosed in the study when the final results were published.
The article also discusses emails produced which suggest that Bayer was attempting to market Yaz and Yasmin for uses not approved by the Food and Drug Administration (FDA). Under the law, drug makers are barred from marketing drugs for off-label uses.
As recently as last month, the FDA warned that based on its own study, women taking birth control pills with drospirenone, the active ingredient in Yaz and Yasmin, may have a 75 percent greater chance of experiencing blood clots and VTEs. The FDA is set to discuss the safety of these drugs on December 8, 2011 during a joint meeting of the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committtee.
If you or someone you know has suffered a VTE or other complication as a consequence of taking Yaz or Yasmin, contact one of our product liability attorneys for a free consultation.